TPD

Accelerator Life Science Partners Launches Biotechnology Startup Company in Singapore with $16M in Series A Commitments

Retrieved on: 
星期三, 九月 27, 2023
Biotechnology, Oncology, Health, Start-Up, Artificial Intelligence, Health Technology, Professional Services, Technology, Proteolysis targeting chimera, University, Therapy, ALSP, Babraham Institute, Cancer, TPD, UCSD, University of California, San Diego, Associate, Science, WEHI, Walter, Artificial intelligence, Organelle, Protein, Medical research, Pharmaceutical industry

Accelerator Life Science Partners (ALSP), an early-stage life science accelerator and investment firm that creates and builds next-generation biotechnology companies centered on innovative science, today announced the Series A financing of Automera, a new biotechnology company that focuses on the development of autophagy-targeting chimera small molecules (AUTACs).

Key Points: 
  • Accelerator Life Science Partners (ALSP), an early-stage life science accelerator and investment firm that creates and builds next-generation biotechnology companies centered on innovative science, today announced the Series A financing of Automera, a new biotechnology company that focuses on the development of autophagy-targeting chimera small molecules (AUTACs).
  • The company was established by co-founders Associate Professor Michael Lazarou, Loong Wang, and Taiyang Zhang at Talo Labs Pte Ltd. in collaboration with ALSP.
  • Automera has secured $16M in Series A funding, a co-led endeavor by ALSP and ClavystBio, with participation from Singapore-based global investor EDBI, Xora Innovation, and other undisclosed investors.
  • “As our first investment in Singapore, Automera exemplifies the innovative scientific and translational research ongoing in the region.

SK Biopharmaceuticals' Proteovant Therapeutics Presents Preclinical Data on IKZF2 Protein Degrader Program and MOPED™ Molecular Glue Screening Platform at the 20th Annual Discovery on Target Conference

Retrieved on: 
星期三, 九月 27, 2023
Central nervous system, Cancer, TPD, Research, CNS, Protein, Growth, Therapy, IKZF2, Conference, Fine chemical

SEOUL, South Korea and KING OF PRUSSIA, Pa., Sept. 26, 2023 /PRNewswire/ -- SK Biopharmaceuticals, a global biotech focused on the research, development and commercialization of treatments for disorders of the central nervous system (CNS) and oncology, and its U.S. R&D subsidiary, Proteovant Therapeutics, today announced they will present data on the discovery and characterization of a selective IKZF2 molecular glue degrader with best-in-class potential, and on MOPED™, a novel platform for the discovery of molecular glues, at the 20th Annual Discovery on Target Conference being held in Boston, September 25-28, 2023.

Key Points: 
  • These presentations are the first in a series in which the companies will unveil exciting results from its targeted protein degradation (TPD) studies and MOPEDTM Molecular Glue Screening Platform.
  • TPD harnesses the body's natural protein disposal system and offers the potential to develop new medicines targeting historically difficult-to-drug proteins that play an important role in causing serious diseases.
  • SK Biopharmaceuticals and Proteovant Therapeutics are discovering and developing potential best-in-class and first-in-class degraders to engage previously undruggable targets.
  • "We are excited to share new data on our IKZF2 molecular glue degrader that demonstrates the potential to combine with immune checkpoint therapies for the treatment of cancer," said Donghoon Lee, President and CEO of SK Biopharmaceuticals and SK Life Science.

SK Biopharmaceuticals’ Proteovant Therapeutics Presents Preclinical Data on IKZF2 Protein Degrader Program and MOPED™ Molecular Glue Screening Platform at the 20th Annual Discovery on Target Conference

Retrieved on: 
星期二, 九月 26, 2023
Central nervous system, Cancer, TPD, Research, CNS, Protein, Therapy, IKZF2, Conference, Fine chemical

These presentations are the first in a series in which the companies will unveil exciting results from its targeted protein degradation (TPD) studies and MOPEDTM Molecular Glue Screening Platform.

Key Points: 
  • These presentations are the first in a series in which the companies will unveil exciting results from its targeted protein degradation (TPD) studies and MOPEDTM Molecular Glue Screening Platform.
  • TPD harnesses the body’s natural protein disposal system and offers the potential to develop new medicines targeting historically difficult-to-drug proteins that play an important role in causing serious diseases.
  • SK Biopharmaceuticals and Proteovant Therapeutics are discovering and developing potential best-in-class and first-in-class degraders to engage previously undruggable targets.
  • “We are excited to share new data on our IKZF2 molecular glue degrader that demonstrates the potential to combine with immune checkpoint therapies for the treatment of cancer,” said Donghoon Lee, President and CEO of SK Biopharmaceuticals and SK Life Science.

Amphista Therapeutics Achieves First Milestone in Second Discovery Programme with Bristol Myers Squibb

Retrieved on: 
星期二, 九月 26, 2023
BMY, TPD, Bristol Myers Squibb, Amphisbaena, NYSE, CNS, Pharmaceutical industry

Cambridge, UK, September 26th, 2023 – Amphista Therapeutics (“the Company” or “Amphista”), a leader in next generation targeted protein degradation (TPD) approaches, today announces it has achieved the first milestone in the second active discovery programme under its strategic collaboration and license agreement with Bristol Myers Squibb (NYSE: BMY), triggering a payment for achieving the milestone.

Key Points: 
  • Cambridge, UK, September 26th, 2023 – Amphista Therapeutics (“the Company” or “Amphista”), a leader in next generation targeted protein degradation (TPD) approaches, today announces it has achieved the first milestone in the second active discovery programme under its strategic collaboration and license agreement with Bristol Myers Squibb (NYSE: BMY), triggering a payment for achieving the milestone.
  • This follows the announcement of the first milestone achieved in the first discovery programme on May 4, 2023 .
  • Louise Modis, Chief Scientific Officer of Amphista Therapeutics said: “The achievement of this first milestone in the second discovery programme under Amphista’s strategic collaboration with Bristol Myers Squibb is a testament to our innovative science and ability to discover and progress at pace differentiated, novel therapeutic molecules for our pharmaceutical partners.
  • Bristol Myers Squibb is granted a global exclusive license to the resulting degraders and will be responsible for further development and commercialization activities.

In-Depth Analysis of the Emerging Targeted Protein Degradation (TPD) Space, 2023 Research Report - Opportunities in Research and Product Development Partnerships to Develop Next-gen TPD Therapeutics - ResearchAndMarkets.com

Retrieved on: 
星期一, 九月 25, 2023
Health, Other Health, Research, Pharmaceutical, Science, Biotechnology, Proteolysis targeting chimera, Growth, R, Research report, Partnership, Proteome, TPD, D, Dietary supplement, Vaccine, Silk

The "Emerging Landscape of Targeted Protein Degradation Therapeutics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Emerging Landscape of Targeted Protein Degradation Therapeutics" report has been added to ResearchAndMarkets.com's offering.
  • This insightful research report delves into the burgeoning field of targeted protein degradation (TPD), a promising approach for treating previously untreatable diseases by precisely targeting disease-causing proteins, minimizing potential side effects.
  • It provides an extensive analysis of various TPD strategies, including extracellular and intracellular protein degraders, their applicability across diseases, key players in clinical translation, and identifies four transformative growth opportunities in the TPD market.
  • What are the R&D trends emerging across TPD that could further shape the development of protein degraders?

OS Achieves 800-Puff Milestone with FEELM Max Technology

Retrieved on: 
星期五, 九月 22, 2023
Retail, Tobacco, Consumer Electronics, Technology, Specialty, Smoker, Prevalence, Electronics, African Queen, OS, TPD, Sensation, Marketing, Longevity, Smoking, Video game, Mobile phone

Recognized as a leading brand in Germany's shisha product market, OS boasts an extensive local network of channels.

Key Points: 
  • Recognized as a leading brand in Germany's shisha product market, OS boasts an extensive local network of channels.
  • As Europe's front-running shisha brand, OS is turbocharging its offerings by integrating the FEELM Max – the globe’s leading ceramic coil disposable solution.
  • Renowned as Germany's most iconic and innovative shisha tobacco brand, OS Tobacco now introduced the new OS VAPES as its first venture into the vaping industry.
  • Harnessing the power of Ceramic Coil Heating Technology and authentic Flavor Reproduction Technology, FEELM merges innovation and electronics to deliver the ultimate sensation and a premium vaping experience.

FEELM and Aroma King Continue European Expansion with Trendsetting Innovations

Retrieved on: 
星期三, 九月 20, 2023
Tobacco, Retail, Specialty, TPD, Sensation, Affection, Traction, Film industry

Aroma King, a leading vape brand renowned from Poland, has unveiled its latest disposable product: The Cosmic Max, further expanding its presence in Europe.

Key Points: 
  • Aroma King, a leading vape brand renowned from Poland, has unveiled its latest disposable product: The Cosmic Max, further expanding its presence in Europe.
  • Since 2020, Aroma King has rapidly made its mark on the European vaping scene.
  • Its product, the Cosmic Max, has gained traction across the European markets, including Spain, France, Belgium, and Austria.
  • Reflecting their industry impact, Aroma King proudly received the "Industry Leader" title at the 2023 Vapouround Awards.

FRESOR Leads the Vaping Industry with Innovative Product Series

Retrieved on: 
星期五, 九月 15, 2023
Taste, Safety, Pinnacle, Child, Cornerstone, TPD, Herbal cigarette, Video game

Its advanced leak-proof structure and exceptional energy efficiency redefine the vaping industry, allowing for more puffs while adhering to TPD regulations.

Key Points: 
  • Its advanced leak-proof structure and exceptional energy efficiency redefine the vaping industry, allowing for more puffs while adhering to TPD regulations.
  • FRESOR 2023 new product launch event stands as a resounding success, showcasing unwavering dedication to innovation and safety.
  • With the formidable FRESOR NOVA and its innovative product series, it is set to revolutionize your vaping experience.
  • FRESOR is about to launch a new product series with a larger capacity and is committed to continuous innovation to bring you the best e-cigarette technology.

Nurix Announces Strategic Collaboration with Seagen Combining Industry Leading Technologies of Targeted Protein Degradation and Antibody-Drug Conjugation to Advance an Innovative New Class of Cancer Therapeutics

Retrieved on: 
星期四, 九月 7, 2023
Therapy, Cancer, TPD, Research, Antibody, Seagen, ET, Patient, Webcast, ADC, Bone marrow, DAC, Safety, Fine chemical, Vaccine

SAN FRANCISCO, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today announced that it has entered into a multi-year, multi-target strategic collaboration agreement with Seagen Inc. to advance a new class of medicines called Degrader-Antibody Conjugates (DACs) for use in cancer. The collaboration between the two companies will focus on an innovative approach to combine two powerful technologies to target cancer—antibody-drug conjugation (ADC) and targeted protein degradation (TPD)—with the goal of creating drugs with new mechanisms of action as well as improved specificity and anti-cancer activity.

Key Points: 
  • As part of the multi-year collaboration, Nurix will use its proprietary DELigase platform to develop a suite of targeted protein degraders against multiple targets nominated by Seagen that are suitable for antibody conjugation.
  • Given the potential to conjugate multiple antibodies to unique degraders, several DAC drugs may be developed and commercialized within this collaboration.
  • At 8:30 a.m., ET, September 7, 2023, Nurix will host a conference call and webcast to discuss this update.
  • A replay of the webcast and call will be archived on the Nurix website for approximately 30 days after the event.

FEELM and OS Vape Make a Joint Debut at Dortmund, Setting a New 800+ Puff Standard for Germany's Disposable Market

Retrieved on: 
星期四, 九月 14, 2023
Tobacco, Retail, Specialty, Taste, Partnership, Exhibition, Culture, OS, TPD, Drinking, Heated tobacco product, System, Smoking, Industrial design

This distinguished gathering provides a platform for industry professionals to interact with top-tier representatives spanning retail, manufacturing, and service sectors.

Key Points: 
  • This distinguished gathering provides a platform for industry professionals to interact with top-tier representatives spanning retail, manufacturing, and service sectors.
  • OS, recognized as a dominant force in Germany's shisha product market, ventured into the disposable vape industry.
  • This represents an impressive 30%+ enhancement in puff count compared to other common disposable products, establishing a new standard under TPD compliance.
  • Given the debut of the 800+ puff disposable product in Germany, there was keen interest in the technical solution behind it.